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responsibility of XAbstract An optimized and validated spectrophotometric method has been developed for the
determination of ceﬁxime in pharmaceutical formulations. The method is based on the complexa-
tion reaction between ceﬁxime and palladium ion in the presence of acidic buffer solution (pH 3) in
ethanol-distilled water medium at room temperature. The complex absorbed maximally at 352 nm.
Beer’s law is obeyed in the working concentration range of 2.5–35 mg/mL with apparent molar
absorptivity of 1.015 104 L/mol cm and Sandell’s sensitivity of 0.001 mg/cm2/0.001 absorbance
unit. The limits of detection and quantitation for the proposed method are 0.175 and 0.583 mg/mL,
respectively. The effect of common excipients used as additives has been studied in the
determination of ceﬁxime. The proposed method has been successfully applied for the determina-
tion of ceﬁxime in pharmaceutical formulations. The results obtained by the proposed method were
statistically compared with the reference method using t and F values and found no signiﬁcant
difference between the two methods.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
.009
652690.
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i’an Jiaotong University.1. Introduction
Ceﬁxime trihydrate (CAS: 79350-37-1, M.W. 507.5) is chemically
known as 7-{[2-(2-amino-1,3-thiazol-4-yl)-2(carboxymethoxyimi-
no)acetyl]amino}-3-ethenyl-8-oxo-5thia-1-azabicyclo oct-2-ene-2-
carboxylic acid. The drug is available in tablets (200 and
400 mg) and suspension (100 mg per 5-mL spoonful). It is given
by mouth in the treatment of susceptible infections including
gonorrhoea, otitis media, pharyngitis, lower respiratory-tractlsevier B.V. All rights reserved.
Quantitative analysis of ceﬁxime by spectrophotometry 249infections especially bronchitis, and urinary-tract infections. It
comes under third generation cephalosporin, effective against a
wide range of sensitive gram-positive, gram-negative and anaero-
bic bacterial pathogens including betalactamase producing strains.
At high concentrations, gastrointestinal side effects, headaches,
dizziness and rashes can appear. Therefore, the analysis of ceﬁxime
is important for obtaining optimum therapeutic concentration and
for quality assurance in pharmaceutical formulations. The drug is
ofﬁcially listed in British Pharmacopoeia [1] which describes a
liquid chromatographic method for its assay in bulk form. In
order to assure the quantity of ceﬁxime in dosage forms, several
methods have been reported which include liquid chromat-
ography-mass spectrometry [2], high performance liquid chroma-
tography [3–6], high performance thin layer chromatography [7,8],
derivative spectrophotometry [9], voltammetry [10], and capillary
electrophoresis [11].
The literature survey revealed that a number of spectrophoto-
metric methods have been reported for the quantitative analysis of
ceﬁxime in pharmaceutical formulations. The estimation of ceﬁx-
ime was performed based on the reaction of drug with ferrihy-
droxamate [12] and Folin–Ciocalteu reagent at 720 nm [13]. The
reaction of ceﬁxime with a mixture of 3-methyl-2-benzothiazo-
linon hydrazone HCl and ferric chloride [14]; ferric chloride and
2,2-bipyridyl [15] have been utilized for its determination in bulk
and dosage forms. Another method is based on the hydrolysis of
b-lactum ring of ceﬁxime with sodium hydroxide which subse-
quently reacts with iodate to liberate iodine in acidic medium. The
liberated iodine oxidizes methylene blue to violet colored species of
maximum absorption at 640 nm and thus is utilized for its assay in
commercial dosage forms [16]. Potassium permanganate oxidizes
ceﬁxime in alkaline medium and itself reduces to manganate ion,
which was measured at 598 nm [17] for the determination of
ceﬁxime in dosage forms. The determination of ceﬁxime has been
done by spectroﬂuorimetry utilizing the reaction of the drug with
2-cyanoacetamide, which exhibits maximum ﬂuorescence intensity
at wavelength 378 nm after excitation at 330 nm [18]. The main
problem associated with these determinations is the more analysis
time with a number of reagents and laborious cleanup procedure
prior to analysis. The sample preparation of the drug included
enrichment, separation techniques such as liquid–liquid or solid–
liquid extraction, coprecipitation, electrodeposition to isolate and
preconcentrate the drug. Therefore, there is a need for a rapid,
simple, accurate and selective spectrophotometric method for the
determination of ceﬁxime in pharmaceutical formulations. Spec-
trophotometry is the best tool for determining drug in the
laboratories of research, hospitals and pharmaceutical industries
due to its low cost, inherent simplicity, versatility, adaptablity and
affordability [19]. The proposed method is based on the formation
of the yellow colored complex between ceﬁxime and Pd(II) in
ethanol-distilled water medium in the presence of buffer solution
of pH 3 at room temperature (2571 1C). The complex absorbed
maximally at 352 nm and the reaction is utilized for the estimation
of drug in pharmaceutical formulations. The reaction conditions
are optimized and validated as per the International Conference
on Harmonisation guidelines [20].
2. Experimental
2.1. Apparatus
All spectral and absorbance measurements were made on a
Helios Alpha UV–vis spectrophotometer (Thermo ElectronCorporation, England, UK) with 1 cm matched quartz cells.
IR spectra were recorded on an IR Afﬁnity-1 spectrophot-
ometer (Shimadzu, Kyoto, Japan) in wave number region
4000–400 cm–1 using KBr pellet technique. pH meter (Hanna,
USA) was used to measure the pH of analyte solution.
2.2. Reagents and standards
All reagents used were of analytical reagent grade. 9.852 104 M
(0.05%) ceﬁxime trihydrate (CAS: 79350-37-1, M.W.: 507.5)
solution was freshly prepared in methanol. The pure ceﬁxime
trihydrate (Batch No XMEO 110023) is provided by National
Pharmaceutical Industries Company, Oman. The solution was
stable up to 12 h.
1.41 103 M palladium chloride (CAS: 7647-10-1, M.W.:
177.32, Iqba Chemie Pvt. Ltd., Mumbai, India) solution was
prepared by dissolving 0.025 g palladium chloride in 5 mL of
0.5 M HCl and the mixture was heated until dissolved
completely and cooled at room temperature before diluted
up to the mark with distilled water in a 100 mL volumetric
ﬂask. Buffer solutions of pH ranging from 2.2 to 3.8 were
prepared by mixing appropriate volumes of 0.2 M Na2HPO4
and 0.1 M citric acid in a total volume of 20 mL [21]. Ceﬁxime
formulations such as Cefrax 200 mg capsule (National Phar-
maceutical Industries Company, Oman) and Suprax 200 mg
tablet (Sanoﬁ-aventis, UK) were purchased locally from
Scientiﬁc Pharmacy (Muscat, Oman).
2.3. Recommended procedure for the determination of ceﬁxime
Aliquots of 0.05–0.7 mL of 0.05% ceﬁxime solution corre-
sponding to 2.5–35 mg/mL were pipetted followed by the
addition of 2.5 mL Na2HPO4–citric acid buffer solution of
pH 3 into a series of 10 mL standard volumetric ﬂasks. To
each ﬂask, 1.4 mL of 1.41 103 M palladium chloride solu-
tion was added and diluted up to the mark with ethanol. The
contents of the ﬂask were mixed well and the absorbance was
measured at 352 nm against the reagent blank prepared
similarly except ceﬁxime within the stability time period of
6 h. The amount of ceﬁxime was obtained either from the
calibration graph or the regression equation.
2.4. Determination of ceﬁxime in pharmaceutical formulations
The powder contents of commercially available Cefrax
capsule and Suprax tablet (20 in number) of 200 mg strength
of ceﬁxime were weighed and grounded. The powder
equivalent to 50 mg ceﬁxime were taken in 60 mL methanol
and kept for 10 min for complete dissolution of the drug.
The mixture was ﬁltered through Whatmann No. 42 ﬁlter
paper (Whatmann International Limited, Kent, UK) in
100 mL standard volumetric ﬂask. The residue was washed
well with 3 10 mL portions of methanol for complete
recovery of the drug and diluted up to the mark with
methanol. The amount of ceﬁxime was determined follow-
ing the recommended procedure.
2.5. Procedure for reference method [15].
Aliquots of 0.1–1.0 mL of 0.01% ceﬁxime were pipetted into a
series of 10 mL standard volumetric ﬂasks. To each ﬂask,
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Fig. 1 Absorption spectra of (A) 0.1 mL of 9.852 104
M ceﬁxime, (B) 0.4 mL of 1.41 103 M palladium chloride and
(C) 0.6 mL of 9.852 104 M ceﬁximeþ1.4 mL of 1.41 10–3 M
Pd(II)þ2.5 mL of Na2HPO4–citric acid buffer solution of pH 2.8. The
solution of A is diluted with methanol while the solutions of B and C
are diluted with distilled water and ethanol, respectively, in 10 mL
standard volumetric ﬂask.
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Fig. 2 Job’s plot for Pd(II)–ceﬁxime complex.
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2-bipyridyl were added. The contents of the ﬂask were heated
at 70 1C for 15 min and then cooled. After cooling, the content
of the ﬂask was diluted up to the mark with distilled water.
The absorbance of the pink colored complex was measured at
520 nm against the reagent blank prepared similarly except
ceﬁxime. The amount of ceﬁxime was obtained either from the
calibration graph or the regression equation.
2.6. Stoichiometry
The stoichiometric reaction between ceﬁxime and palladiu-
m(II) was studied by Job’s method of continuous variations
[22]. For this purpose, different volumes of 9.852 104 M
ceﬁxime were added with different volumes of 9.852 104 M
palladium(II) chloride, respectively, followed by the addition
of 2.5 mL buffer solution of pH 3 in 10 mL standard
volumetric ﬂask. The contents of the ﬂask were diluted up
to the mark with ethanol. The absorbance was recorded at
352 nm and plotted against the mole fraction of ceﬁxime.
2.7. Validation
The proposed method has been validated for linearity, sensitivity,
precision, accuracy, robustness, speciﬁcity and evaluation of bias.
2.7.1. Linearity, limit of detection and limit of quantitation
The linearity of the proposed method was assessed at nine
different concentrations: 2.5, 5, 10, 15, 20, 25, 30, 32.5 and
35 mg/mL. Each concentration level was independently ana-
lyzed repeatedly for ﬁve times. The absorbance obtained ateach concentration was plotted against the concentration of
ceﬁxime in mg/mL. The linear regression equation was eval-
uated by least square treatment of the calibration data. The
other statistical parameters of the proposed method were
calculated using OriginPro 6.1 Software.
The limit of detection (LOD) and the limit of quantitation
(LOQ) for the proposed method were calculated using the
following equations [23]:
LOD¼ 3 S0
b
LOQ¼ 10 S0
b
where S0 is standard deviation of calibration line and b is
the slope.
2.7.2. Precision
The precision of the proposed method was evaluated by intra-
day and inter-day precisions at three concentration levels
(5.0, 15.0 and 30.0 mg/mL) of ceﬁxime. Each concentration
level was independently analyzed repeatedly for ﬁve times
within a day (intra-day precision) and over ﬁve consecutive days
(inter-day precision). The standard deviation (SD) and %
relative standard deviation (RSD) were calculated.
2.7.3. Accuracy
The accuracy of the proposed method was tested by analyzing
freshly prepared capsule and tablet formulated drug solution
in ﬁve replicates. The same drug solution was also tested by
reference method. The percent recovery and standard devia-
tions of the two methods were compared and tested for
accuracy of the proposed method.
The accuracy of the proposed method was also checked by
standard addition technique. In this technique, 0.4 mL of the
0.5 mg/mL of the formulated capsule (or tablet) sample
solution was spiked separately with 0, 0.05, 0.1, 0.15 and
0.2 mL of the reference drug sample solution in 10 mL
standard volumetric ﬂask and diluted up to the mark with
ethanol. Each level was independently analyzed repeatedly for
Fig. 3 Infra-red spectra of (A) pure ceﬁxime and (B) Pd–ceﬁxime complex.
Quantitative analysis of ceﬁxime by spectrophotometry 251ﬁve times. The nominal value of the ceﬁxime concentration in
capsule and tablet was determined by dividing the obtained
intercept by slope.2.7.4. Speciﬁcity
The speciﬁcity of the proposed method was investigated by
observing any interference encountered from common excipi-
ents of the pharmaceutical formulations such as starch,
fructose, glucose, lactose, sodium benzoate and phenyl alanine
at 30 mg/mL ceﬁxime.2.7.5. Robustness
The robustness of the proposed method was evaluated by
challenging each operational parameter of the proposed
method such as: 1.470.2 mL of 1.41 103 M palladium
chloride; buffer solution of pH 370.2; working temperature,
25C71 1C, color development time, immediately.
2.7.6. Applicability and evaluation of bias
The point and interval hypothesis tests have been performed
to compare the results of the proposed method with those of
the reference method at 95% conﬁdence level. The bias was
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Scheme 1 Reaction sequence of the proposed method.
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Fig. 4 Effect of the volume of 1.41 103 M palladium chloride.
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Fig. 5 Effect of pH on the absorbance of Pd(II)–ceﬁxime
complex.
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Fig. 6 Effect of solvent on the absorbance of Pd(II)–ceﬁxime
complex.
Table 1 Optical and regression characteristics of the
proposed method.
Parameters Analytical data
lmax (nm) 352 nm
Beer’s law limit
(mg/mL)
2.5–35
Molar absorptivity
(L/mol cm)
1.015 104
Sandell’s sensitivity 0.001 mg/cm2/0.001
absorbance unit
Linear regression equationa A¼3.772 104
þ2.002 102C
Sa 7.523 104
7tSa 1.78 103
Sb 3.341 105
7tSb 7.901 105
Correlation coefﬁcient (r) 0.9999
Variance (So
2) 1.30 106
LOD (mg/mL) 0.175
LOQ (mg/mL) 0.583
aWith respect to A¼aþbC, where C is the concentration in
mg/mL and A is absorbance.7tSa and7tSb are the conﬁdence
limits for intercept and slope, respectively.
Table 2 Precision of the proposed method.
Actual concentration
(mg/mL)
Intra-day assay
Measured concentration
7SD (mg/mL);
RS
5.0 5.0170.08 1.5
15.0 15.0170.05 0.1
30.0 30.0270.08 0.2
aMean for ﬁve independent analysis.
Quantitative analysis of ceﬁxime by spectrophotometry 253evaluated by an interval hypothesis test based on the mean
values of the proposed method and the reference method. The
proposed method is considered acceptable when its true mean
is within 72.0% of that of the reference method. The lower
(yL) and the upper (yU) acceptance limits can be calculated by
the following quadratic equation [24]:
y2 x21S2pttab2=n1
 
þ y 2x1x2ð Þ þ x22S2pttab2=n2
 
¼ 0
where x1and x2 are the mean values at n1 and n2 measure-
ments, respectively. Sp is the pooled standard deviation and
ttab is the tabulated one-sided t-value at 95% conﬁdence level.3. Results and discussion
3.1. UV–visible spectrophotometric spectra analysis
The absorption spectrum of methanolic solution of ceﬁxime
absorbed maximally at 210 and 290 nm whereas the absorption
spectrum of aqueous solution of palladium chloride (pH 2.1)
showed two bands at 208 and 236 nm. When the two solutions
were mixed together, a red shift in the wavelength is observed due
to the complexation reaction between ceﬁxime and Pd(II) in the
presence of acidic buffer solution. The Pd(II)–ceﬁxime complex
exhibited only one band with lmax of 352 nm. The absorption
spectra of ceﬁxime, palladium chloride and Pd(II)–ceﬁxime
complex are shown in Fig. 1. The absorbance measurement at
352 nm as a function of ceﬁxime concentration is exploited to
develop a new, accurate and rapid spectrophotometric method
for the determination of ceﬁxime in pharmaceutical formulations.
The reaction was carried out at room temperature (25 1C) and the
coloured complex was stable up to 6 h.
3.2. Stoichiometry
The stoichiometric ratio between ceﬁxime and Pd(II) was
evaluated by Job’s method of continuous variations. The
Job’s plot (Fig. 2) has conﬁrmed that 1 mol of ceﬁxime was
reacted with 1 mol of Pd(II). Thus, the stoichiometry of the
complex is established and found to be 1:1. The apparent
formation constant (Kf) for the complex between Pd(II) and
ceﬁxime is calculated using the following expression:
Kf ¼
ðAobs=AextpÞC
½CMðAobs=AextpÞC ½CLðAobs=AextpÞC 
where Aobs. and Aextp are observed and extrapolated absor-
bance values of the complex at [Pd–ceﬁxime] and C in M,Inter-day assay
D (%)a Measured concentration
7SD (mg/mL);
RSD (%)a
1 4.9970.08 1.65
2 14.9970.07 0.50
7 29.9970.10 0.32
Table 3 Test of accuracy in Cefrax capsule and Suprax tablet by standard addition technique.
Concentration (mg/mL) Linear regression parameters Recoveryb (%)
Sample Standard Nominal Error (Xe) Intercept Slope r
a
Cefrax (20.0) 0, 2.5, 5, 7.5, 10 20.03 0.32 0.4006 0.02 0.9999 100.15
Suprax (20.0) 0, 2.5, 5, 7.5, 10 19.94 0.24 0.3996 0.02 0.9999 99.97
aCoefﬁcient of correlation.
bMean for ﬁve independent analyses.
Table 4 Effect of foreign species on the determination of
30 mg/mL ceﬁxime.
Sample number Foreign species Maximum
tolerance
limit (mg/mL)
1 Glucose 900.10
2 Fructose 900.10
3 Lactose 450.4
4 Starch 1711.6
5 Sodium benzoate 720.6
6 Phenyl alanine 900.1
S.N.H. Azmi et al.254respectively, where C is the limiting concentration. Thus, Kf
for the complex was found to be 1.138 105. The apparent
Gibbs free energy (DG1) is calculated using DG1¼2.303 RT
log Kf and found to be 28.85 kJ/mol, conﬁrming the
feasibility of the reaction.
3.3. Infra red spectra analysis
The infra-red spectra of pure ceﬁxime and Pd(II)–ceﬁxime
complex are shown in Fig. 3A and B, respectively. Ceﬁxime
has –NH2,–COOH, –CONH and C¼O lactam groups which
are the potential sites for coordination with metal ions.
Comparison of an IR spectrum of the complex with those of
pure ceﬁxime indicates that the lactam (C¼O) band appears
at 1766 cm1 in the pure ceﬁxime while the complex shows this
band at 1772 cm1 suggesting that no coordination occurs
with palladium ion. The amide carbonyl band, n(C¼O)–NH
in the pure ceﬁxime appears at 1674 cm1 with a weak
shoulder at 1633 cm1 while the Pd(II)–ceﬁxime complex
shows this band at 1676 cm1 with a prominent peak at
1633 cm1 suggesting that ceﬁxime coordinated with Pd(II)
through the nitrogen atom. The asymmetrical and symmetrical
stretching bands of carboxylate groups change from 1537 to
1541 cm1 and 1352 to 1404 cm1, respectively, due to the
coordination. The Pd–N stretching vibration occurs at
495 cm1 [25]. A tentative mechanism for the complexation
of Pd(II)–ceﬁxime complex is given in Scheme 1.
3.4. Optimization of variables
The optimization of variables was investigated by testing
reaction time, concentration of ceﬁxime, solvents and buffer
solution of different pH.
The effect of reaction time on the absorbance of Pd(II)–
ceﬁxime complex and its stability was investigated. ThePd(II)–ceﬁxime complex got stabilized immediately at
2571 1C and remained stable for 6 h.
The effect of the volume of 1.41 103 M palladium on the
absorbance of complex was investigated in the range 0.2–
1.6 mL. It is evident from Fig. 4 that the maximum absor-
bance was obtained with 1.2 mL of 1.41 103 M palladium.
Above this volume up to 1.6 mL of 1.41 103 M palladium,
the absorbance remained unchanged. Therefore, 1.4 mL of
1.41 103 M palladium chloride was used in the determina-
tion process of ceﬁxime.
The inﬂuence of pH on the absorbance of the Pd(II)–
ceﬁxime complex with 30.0 mg/mL ceﬁxime was investigated in
the pH range of 2.2 to 3.8 using disodium hydrogen
phosphate–citric acid buffer. The maximum absorbance was
obtained in the pH range of 2.8–3.2 and above this, the
absorbance value decreased (Fig. 5 ). Therefore, the buffer
solution of pH 3.0 was selected for all absorbance measure-
ments in the determination of ceﬁxime in pharmaceutical
formulations.
The effects of solvents such as methanol, acetone, acetoni-
trile, ethanol, 1,4-dioxan, dimethylformide (DMF) and dis-
tilled water were investigated on the absorbance of the Pd(II)–
ceﬁxime complex. The absorbance of Pd(II)–ceﬁxime complex
using 30.0 mg/mL ceﬁxime diluted with various solvents is
recorded at 352 nm and shown in Fig. 6. It is clear from the
ﬁgure that the highest absorbance was obtained in ethanol.
Therefore, ethanol was selected as the best solvent for the
determination of ceﬁxime in drug formulations.
3.5. Validation
3.5.1. Linearity, LOD and LOQ
Under the optimized experimental conditions, the calibration
graph was constructed by plotting the absorbance against
initial concentration of ceﬁxime at nine independent concen-
tration levels. Beer’s law is obeyed in the concentration ranges
of 2.5–35 mg/mL with apparent molar absorptivity of
1.015 104 L/mol cm and Sandell’s sensitivity of 0.001 mg/
cm2/0.001 absorbance unit. The linear regression equation is
obtained by statistical treatment of the calibration data which
is ﬁtted with the straight line equation in the form of
A¼aþbC, where A is absorbance at 352 nm, C is concentra-
tion in mg/mL, b is slope and a is intercept of calibration line.
The high value of correlation coefﬁcient (0.9999) indicated
excellent linearity (Table 1). The experimental intercept of the
calibration line was tested for signiﬁcance of deviation from
the theoretical intercept, i.e., zero. For this justiﬁcation,
t-value calculated from relation, t¼a/Sa [26] is found to be
0.501, which did not exceed the tabulated t-value (2.365, n¼7)
at 95% conﬁdence level. This indicated that the intercept in
Table 5 Signiﬁcance of testing: Point and interval hypothesis tests for the determination of ceﬁxime in pharmaceutical
formulations at 95% conﬁdence level.
Pharmaceutical formulation (s) Proposed method Reference method t- & F valuesa yL
b yU
b
Recovery RSDc Recovery RSDc
(%) (%) (%) (%)
Cefrax capsule 200 mg 100.11 0.447 99.89 0.191 t¼1.02 F¼5.48 0.991 1.004
Suprax tablet 200 mg 99.91 0.224 99.89 0.191 t¼0.152 F¼1.375 0.996 1.004
aTheoretical t (n¼8) and F-values (n¼4, 4) at 95 % conﬁdence level are 2.306 and 6.39, respectively.
bA bias, based on recovery experiments, of 72% is acceptable.
cMean for ﬁve independent analyses.
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signiﬁcantly different from zero. Thus, the proposed method
is free from procedural error.
3.5.2. Precision
The intra-day and inter-day precisions were evaluated by
determining the concentration of ceﬁxime at lower, middle
and upper concentration levels for ﬁve repeated times within
the same day and on ﬁve consecutive days, respectively. The
results and their statistical analysis are summarized in Table 2.
It is clear from the table that the values of RSD (intra-day and
inter-day precisions) were in the ranges of 0.12–1.65%,
respectively. It can be seen from the table that RSD values
were precise and can be used to determine ceﬁxime in the
pharmaceutical formulations.
3.5.3. Accuracy
The accuracy of the proposed method was investigated by
performing recovery experiments through standard addition
technique. The absorbance is recorded for all standard addi-
tion solutions and the results of analyses are summarized in
Table 3. It is clear from the table and the graph that the
linearity of the regression line for capsule and tablet formula-
tion samples were good. It is evident from the ﬁgure that the
concentration of ceﬁxime in pharmaceutical formulations is
given by intercept/slope. The ratio of the intercept and the
slope of the regression line is subjected to error (SxE). SxE is
calculated from the following expression
SxE ¼
Sy=x
b
1
n
þ y
2
b2
P
i
ðxixÞ2
2
64
3
75
1=2
and found to be 0.32 and 0.24 mg/mL, respectively, for capsule
and tablet formulation samples. The conﬁdence limit for the
concentration of ceﬁxime in pharmaceutical formulations is
calculated byxE7tSxEat n2 degrees of freedom and found to
be 20.0370.32 and 19.9470.24 mg/mL, respectively. The most
attractive feature of the proposed method using standard
addition method is its relative freedom from various excipients
found in drug formulations.
3.5.4. Speciﬁcity
The effect of excipients added as additives on the determina-
tion of 30 mg/mL ceﬁxime was studied. For this purpose, the
varying concentrations of excipients such as starch, fructose,
glucose, lactose, sodium benzoate and phenyl alanine with30 mg/mL ceﬁxime were taken and the absorbance was
recorded to know the concentration of ceﬁxime. Table 4 shows
the maximum tolerance value of the studied excipients. The
maximum tolerance value was taken, when the absorbance
value did not exceed 72% on addition of excipients.
3.5.5. Robustness
The robustness of the proposed method was established by
deliberately changing the volume of 1.41 103 M Pd(II),
1.4 mL (70.2 mL) for the determination of ceﬁxime. The
capsule and tablet formulated sample solutions containing
10 mg/mL ceﬁxime were analyzed ﬁve times repeatedly by the
proposed method. Percentage recovery and RSD were found
to be 100.11% and 0.447% for capsule and 99.91% and
0.224% for tablet, indicating the robustness of the proposed
method.
3.5.6. Applicability and evaluation of bias
The applicability of the proposed method for the determina-
tion of ceﬁxime in pharmaceutical formulation samples has
been studied. Results of the proposed method were statistically
compared with those of reference method using point and
interval hypothesis tests. The paired t- and the F-values at
95% conﬁdence level were calculated and found to be less than
the tabulated t(2.036 at u¼8) and the F-values (6.39 at
u¼4,4) at 95% conﬁdence level [27], thus conﬁrming no
signiﬁcant difference between the performance of the proposed
method and the reference method (Table 5). The bias calcu-
lated by interval hypothesis test in the form of lower limit (yL)
and upper limit (yU) were in the range of 0.98–1.02. Thus, the
proposed method is suitable for routine analysis of ceﬁxime in
dosage forms. The speed of analysis and less number of
reagents utilized in the proposed method are the main
advantages of the proposed method as compared to reference
method.4. Conclusions
The proposed method is a simple, rapid and accurate for the
determination of ceﬁxime in capsule and tablet formulations.
The method has advantage of using a commonly available
solvent, i.e., ethanol with the use of palladium as a reagent.
The proposed method has avoided the use of heating the
reaction mixture and can be used as an alternate method for
routine quality control analysis of ceﬁxime in pharmaceutical
and biological samples.
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